RxDoctor Payments Data

Hilary Thompson, PA

Medical · Supply, NCNPI 1841401437

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.7% of the total across 343 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,144in general payments, 2019–2025

Across 343 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$709
  • Novartis$699
  • Regeneron Healthcare Solutions, Inc.$609
  • Sun Pharmaceutical Industries Inc.$608
  • UCB, Inc.$535
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,87996%
  • Education$2654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,144 in reported general payments places this provider in the 90th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina →

Medicare billing

Part B allowed, 2024
$368,752
Medicare patients
1,793
Services billed
9,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$244,774
Humira(Cf) PenAdalimumab14$189,931
Dupixent PenDupilumab21$84,539
Taltz AutoinjectorIxekizumab12$81,329
Ketoconazole396$6,534
Clobetasol Propionate181$6,409
Metronidazole63$4,566
Tacrolimus17$4,160
Betamethasone Dipropionate76$3,940
Fluorouracil61$3,724
Clindamycin Phosphate94$3,501
Ciclopirox83$3,240
Triamcinolone Acetonide214$2,393
Tretinoin25$2,238
Azelaic Acid20$2,115

Paid to pharmacies, not to this prescriber.

Other medical in Supply

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →